Drug Database
T-

T-Bactum (EB23 18235Y / EB2318235Y)

✓ Approved

Essex Bio-Technology Limited · therapeutic agent

What is T-Bactum?

T-Bactum is a therapeutic agent developed by Essex Bio-Technology Limited. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesEB23 18235Y, EB2318235Y
CompanyEssex Bio-Technology Limited
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Essex Bio-Technology Limited

Therapeutic Indications

T-Bactum is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsOral infection✓ Approved

Related Research Articles

PubMedCurrent microbiology2026-10-15

Diversity and Functional Screening of Trichoderma Species from Soils in Nanchang, China.

Qiu Yanan Y, Fan Lili L, Fu Kehe K, Xiong Min M et al.

A total of 111 Trichoderma isolates were obtained from soil samples collected in Nanchang, China. Based on morphological characteristics and molecular phylogenetic analysis of the translation elongation factor 1-alpha (tef1) gene, these isolates were assigned to 16 distinct phylogenetic lineages closely related to known species, with T. semiorbis, T. asperellum, and T. koningiopsis being the most predominant, accounting for 29, 22, and 16 isolates, respectively. All isolates were functionally screened for the production of five industrially relevant enzymes (laccase, xylanase, cellulase, chitinase, and amylase) and for copper tolerance. Several strains exhibited remarkable enzymatic activities: T. asperellum TasJK96 demonstrated the highest phenol oxidase activity (1.95 ± 0.12 U·mL- 1), T. virens TviJK51 excelled in xylanase production (41.49 ± 1.02 U·mL- 1), T. afroharzianum Tafxt15 exhibited the highest cellulase activity (22.56 ± 0.70 U·mL- 1), T. lentinulae TleJK44 was the top chitinase producer (22.21 ± 0.83 U·mL- 1), and T. koningiopsis TkoJK88 demonstrated the highest amylase activity (91.26 ± 2.25 U·mL- 1). Furthermore, 13 isolates displayed tolerance to copper, with T. virens TviJK10 exhibiting growth at concentrations up to 4.90 mmol·L- 1. This study expands our understanding of Trichoderma diversity in the Nanchang region and provides a collection of promising candidate strains for future biotechnological and bioremediation applications.

PMID 42875536
Read full article →
PubMedMolecular medicine (Cambridge, Mass.)2026-10-15

Elucidating the mechanism underlying incomplete immune recovery in people living with HIV through CD4⁺ and CD8⁺ T cell multi-omics.

Flores-Piñas Marina M, Chafino Silvia S, Viladés Consuelo C, Domingo Pere P et al.

A subset of people living with HIV (PLHIV), known as immunological non-responders (INR), fails to achieve adequate CD4⁺ T cell recovery despite viral suppression with antiretroviral therapy (ART). These individuals face an increased risk of adverse clinical outcomes. This study aims to explore the intracellular mechanisms and molecular signatures underlying this incomplete immune recovery using a multi-omics approach. The study analysed CD4⁺ and CD8⁺ T cells from 100 ART-naïve PLHIV. Participants were classified into controls (baseline CD4⁺ > 200 cells/µL, n = 49) and cases (baseline CD4⁺ ≤ 200 cells/µL, n = 51). Cases were further categorised after 48 weeks of ART as immunological responders (IR, n = 34) or INR (n = 16) based on a recovery cut-off of 250 cells/µL. The research employed integrative proteomic and metabolomic analyses, adjusted for sex, complemented by miRNA and qRT-PCR validation in a subset of samples to identify differential molecular signatures. In CD4⁺ T cells, a baseline signature of 381 proteins and 45 metabolites significantly differentiated controls from cases; notably, 34 proteins and 16 metabolites specifically discriminated future IR from INR before starting treatment. CD8⁺ T cells showed a more limited signature with minimal stratification between IR and INR. Integrative analysis revealed coordinated dysregulation in CD4⁺ T cells of INR, characterised by altered glycolytic flux, metabolic exhaustion, and oxidative stress. Exploratory analyses via miRNA and qRT-PCR confirmed these findings and suggested post-transcriptional mechanisms contribute to the impairment. Incomplete immune recovery in PLHIV is primarily driven by pre-existing metabolic dysfunction and oxidative stress within CD4⁺ T cells, rather than CD8⁺ T cells. These findings identify specific molecular signatures present before ART initiation, highlighting early potential therapeutic targets and strategies to enhance immune reconstitution in this vulnerable population.

PMID 42875740
Read full article →
PubMedBMC cancer2026-10-15

Decoupling T cell cytotoxicity: a CCL21+ICAM1-based synthetic immune niche enhances tumor elimination by accelerating lytic hit delivery.

Gupta Manish Kumar MK, Zoabi Rawan R, Yado Sofi S, Starruß Jörn J et al.

Preserving T cell cytotoxic function during ex vivo expansion remains a major challenge for adoptive cancer immunotherapy. A synthetic immune niche (SIN) composed of immobilized CCL21 and ICAM1 was shown to improve T cell expansion while preserving cytotoxicity; however, it remains unclear which specific step of the T cell killing process is enhanced by the SIN stimulation. Here, we combined advanced imaging based on time-lapse microscopy with a mean-field model to analyze the distinct stages in killing of B16 melanoma cells by CD8[Formula: see text] T cells. This framework enabled us to resolve the tumor cell killing process into discrete steps throughout target cell engagement with SIN-treated T cells and lytic hit delivery. We found that tumor cell death is best explained by a multi-hit process, requiring approximately four discrete hits to trigger cell death. Model-based analysis identified a significant increase in the lytic hit-delivery rate, [Formula: see text], as the main kinetic change associated with the enhanced cytotoxicity of SIN-treated T cells. The target encounter rate, [Formula: see text], could not be reliably compared between conditions because it was practically non-identifiable in the untreated dataset. Global sensitivity analysis further showed that increasing lytic hit delivery has a stronger effect on tumour control than increasing target encounter rates. These findings fundamentally reorient our understanding of optimized T cell manufacturing, suggesting that the lytic execution step may be the primary rate-limiting bottleneck in this in-vitro system, and that engineering strategies targeting granule polarization or discharge warrant prioritization alongside affinity-enhancement approaches.

PMID 42875767
Read full article →
PubMedJournal of contemporary brachytherapy2026-10-15

Applicator-dependent differences between TG-43 and a grid-based Boltzmann solver in iridium-192 high-dose-rate gynecological brachytherapy.

Pavičar Bojan B, Milosavljević Andrej A, Predojević Branko B, Petrović Borislava B

To compare TG-43 and Acuros® BV dose estimates in iridium-192 (192Ir) high-dose-rate (HDR) gynecological brachytherapy across four applicator types and evaluate applicator-dependent differences. The novelty was the systematic comparison of multiple applicators within a single-institution workflow. This retrospective dosimetric study included 40 patients and 121 treatment plans: tandem and ring (T&R, 34 plans), tandem and ovoid (T&O, 38 plans), segmented cylinder (SC, 23 plans), and universal multi-channel cylinder (UMC, 26 plans). All plans were generated in BrachyVision™ v. 15.6 using the TG-43 formalism and subsequently recalculated with Acuros® BV, with identical dwell positions and dwell times. The main analysis included high-risk clinical target volume (HR-CTV) D90, D98, and V100; organ-at-risk (OAR) D2cc; Point A for T&R/T&O; and the SC 100% prescription-isodose position at 5 mm depth. Exploratory dwell-loading descriptors and a density-cap quality assurance audit supported physical and methodological interpretation. TG-43 yielded consistently higher dose estimates than Acuros® BV. For HR-CTV D90, relative differences were 2.9 ±0.5% for T&R, 3.7 ±0.8% for T&O, 3.2 ±0.4% for SC, and 4.9 ±2.2% for UMC. OAR D2cc differences were also largest for UMC, ranging from 4.3% (3.4-7.1%) in bladder to 6.1 ±2.2% in small bowel. For SC, when the TG-43 100% prescription isodose was normalized to 5 mm from the applicator surface, the corresponding Acuros® BV 100% isodose position was 4.6 ± 0.1 mm, indicating an inward shift of 0.4 ±0.1 mm. TG-43 systematically overestimated dose relative to Acuros® BV in all applicator groups. Differences were smallest for T&R, largest and most variable for UMC, and intermediate for T&O and SC. Algorithm-related dose differences are applicator-dependent and should not be assumed uniform across treatment configurations.

PMID 42876950
Read full article →
PubMedHaematologica2026-10-15

Outcomes of ibrutinib plus lenalidomide combination in patients with large Bcell lymphoma refractory to or relapsing after CAR-T-cell therapy and who failed or were ineligible for bispecific antibodies: a multicenter real-world REALI-T study.

Rudebeck Carl Johan CJ, Fornecker Luc Matthieu LM, Guffroy Blandine B, Fouillet Ludovic L et al.

Not available.

PMID 42876292
Read full article →
PubMedFrontiers in immunology2026-10-15

Case Report: Relapse of SLE associated with EBV infection in a patient after CAR-T cell therapy: a clinical case.

Zeng Ping P, Ren Qi Q, Gao Xianfei X, Xian Wei W et al.

We present the case of a 13-year-old boy with refractory systemic lupus erythematosus (SLE) who achieved drug-free remission after anti-CD19 CAR-T cell therapy, but subsequently experienced Epstein-Barr virus (EBV) reactivation on day 142 after CAR T-cell infusion and peak EBV load was 24,400 IU/mL with a severe drop in platelets to 8×109/L, which leading to relapse of SLE and manifestations of chronic active EBV disease (CAEBVD). The whole exogenous gene testing found X chromosome Xp22.33q28 region (chrX: 200855-155239820) a duplicate of about 155.04Mbp,which is associated with the development of Klinefelter syndrome (KS).The temporal association between EBV resurgence and SLE flare suggests that CAR-T-induced immunosuppression with some genetic background may permit EBV reactivation, which can be associated with the return of autoimmunity. This case highlights the need for vigilant monitoring for opportunistic infections and genetic background, particularly EBV, after CAR-T therapy for autoimmune diseases, as they may contribute to disease relapse.

PMID 42876831
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about T-Bactum